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ABSTRACT Inhibition of cyclooxygenase (COX)-2
increases cardiovascular deaths. Identifying a bio-
marker of COX-2 is desirable but difficult, since COX-1
and COX-2 ordinarily catalyze formation of an identical
product, prostaglandin H2. When acetylated by aspirin,
however, COX-2 (but not COX-1) can form 15(R)-
HETE, which is metabolized to aspirin-triggered li-
poxin (ATL), 15-epi-lipoxin A4. Here we have used
COX-1- and COX-2-knockout mice to establish whether
plasma ATL could be used as a biomarker of vascular
COX-2 in vivo. Vascular COX-2 was low but increased
by LPS (10 mg/kg; i.p). Aspirin (10 mg/kg; i.v.) inhib-
ited COX-1, measured as blood thromboxane and
COX-2, measured as lung PGE2. Aspirin also increased
the levels of ATL in the lungs of LPS-treated wild-type
C57Bl6 mice (vehicle: 25.59.3 ng/ml; 100 mg/kg:
112.07.4 ng/ml; P<0.05). Despite this, ATL was
unchanged in plasma after LPS and aspirin. This was
true in wild-type as well as COX-1/ and COX-2/
mice. Thus, in mice in which COX-2 has been induced
by LPS treatment, aspirin triggers detectable 15-epi-
lipoxin A4 in lung tissue, but not in plasma. This
important study is the first to demonstrate that while
ATL can be measured in tissue, plasma ATL is not a
biomarker of vascular COX-2 expression.—Kirkby,
N. S., Chan, M. V., Lundberg, M. H., Massey, K. A.,
Edmands, W. M. B., MacKenzie, L. S., Holmes, E.,
Nicolaou, A., Warner, T. D., Mitchell, J. A. Aspirin-
triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in
the lungs of LPS-treated mice but not in the circula-
tion: implications for a clinical test. FASEB J. 27,
3938–3946 (2013). www.fasebj.org
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Cyclooxygenase (COX) enzymes catalyze the conver-
sion of arachidonic acid to prostaglandin H2, an unsta-
ble intermediate, which is the precursor to a range of
end-product prostanoid mediators, including prostacy-
clin (PGI2), thromboxane A2 (TXA2), and prostaglan-
din (PG) E2. Two isoforms of COX exist (1). COX-1 is
constitutively expressed in most tissues and produces
prostanoids responsible for normal physiological func-
tions such as hemostasis and mucosal integrity. COX-2
is primarily considered to be an inducible isoform. It is
sparsely present in most healthy tissues (1), but is
up-regulated by inflammatory and mitogenic stimuli
and produces prostanoids that potentiate pain and
inflammation. Inhibitors of COX-2, both traditional
nonsteroidal anti-inflammatory drugs (NSAIDs), such
as ibuprofen and diclofenac, which inhibit both COX-1
and COX-2, and newer selective COX-2 agents, such as
rofecoxib and celecoxib (2), have been widely used for
the treatment of arthritis and other inflammatory con-
ditions. Although they are effective for these indica-
tions, it has become clear that chronic use of inhibitors
of COX-2 (both selective and traditional NSAIDs) is
associated with an increased risk of cardiovascular
events, particularly myocardial infarction (3). The
mechanisms responsible for this cardiovascular toxicity
are not fully understood but may reflect loss of cardio-
protective prostanoid pathways in particular patients in
whom COX-2 is abnormally present in the vascular wall
of the renal, cardiac, or systemic circulation. This raises
1 Correspondence: Cardiothoracic Pharmacology, National
Heart and Lung Institute, Imperial College London, Dove-
house St., London SW3 6LY, UK. E-mail: J.A.M., j.a.mitchell@
imperial.ac.uk; N.S.K., n.kirkby@imperial.ac.uk
This is an Open Access article distributed under the terms of
the Creative Commons Attribution 3.0 Unported (CC BY 3.0)
(http://creativecommons.org/licenses/by/3.0/deed.en_US)
which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
doi: 10.1096/fj.12-215533
Abbreviations: 5-LO, 5-lipoxygenase; COX, cyclooxygenase;
ATL, aspirin-triggered lipoxin (15-epi-lipoxin A4); HETE,
hydroxyeicosatetraenoic acid; LC-MS/MS, liquid chromatog-
raphy-tandem mass spectrometry; LPS, lipopolysaccharide;
NSAID, nonsteroidal anti-inflammatory drug; PGI2, prostacy-
clin; PG, prostaglandin; TX, thromboxane; WT, wild type
3938 0892-6638/13/0027-3938 © The Author(s)
the important possibility that screening for cardiovas-
cular COX-2 expression may identify specific individu-
als at higher or lower risk of NSAID-induced cardiovas-
cular toxicity.
The accepted standard for assessing prostanoid pro-
duction in vivo is the measurement of urinary prosta-
noid metabolites. The true source of these metabolites
is not clear, however, and it is being increasingly
questioned whether these markers reflect systemic pro-
stanoid biosynthesis (4–6) or a more localized pool.
Indeed, we have recently shown that while COX-2
drives urinary markers of PGI2, COX-1 is responsible
for levels in the circulation (5). Most importantly,
measurements of regular COX metabolites can never
irrefutably distinguish COX-1 from COX-2-dependent
synthetic pathways because both isoforms normally
catalyze an identical reaction. Aspirin inhibits the abil-
ity of both isoforms to convert arachidonic acid to
PGH2 by acetylation of a key serine residue in the active
site (7). In the presence of aspirin, however, the
catalytic activity of COX-1 and COX-2 is differently
altered (8, 9). Specifically, in vitro aspirin-acetylated
COX-2 gains the ability to convert arachidonic acid to
15(R)-hydroxyeicosatetraenoic acid [15(R)-HETE; refs.
8–10]. Further, in endothelial cell and leukocyte cocul-
tures, endothelial cell-derived 15(R)-HETE can un-
dergo transcellular metabolism by leukocyte 5-lipoxy-
genase (5-LO) to form 15-epi-lipoxin A4 (10), a novel
lipid mediator reported to possess proresolution activ-
ity in situations of inflammation (11). As far as is
known, this pathway is absolutely dependent on aspirin-
acetylated COX-2 and cannot be mediated by COX-1.
In addition, COX-independent pathways for 15(R)-
HETE and 15-epi-lipoxin A4 formation have been de-
scribed involving cytochrome P450 enzymes (12), non-
enzymatic oxidation of arachidonic acid (13), or
phosphorylated 5-LO (14). These may be enhanced by
statins (14, 15) but are not triggered by aspirin. Here,
we have investigated whether aspirin-triggered forma-
tion of 15-epi-lipoxin A4 [aspirin-triggered lipoxin
(ATL)] could provide a plasma biomarker of vascular
COX-2 activity. We reveal that while ATL can be
detected in mouse plasma, levels do not correlate with
the expression level of COX-2 in the vasculature, sug-
gesting that ATL is not a suitable means for the
noninvasive screening of patients for vascular COX-2
expression.
MATERIALS AND METHODS
Animals
COX-1/ (16) and COX-2/ mice (17) were backcrossed for
7 generations onto a C57Bl/6 background (Harlan Bio-
products, Bicester, Oxon, UK). Wild-type (WT) mice were
generated by intercrossing C57Bl/6 backcrossed COX-1/
and COX-2/ mice. All mice used in the study were geno-
typed to establish COX-1 and COX-2 status before use. All
experiments were performed on male and female 10- to 12-wk
old mice and were conducted in accordance with Animals
(Scientific Procedures) Act 1986 and after local ethical review
by the Imperial College London Ethical Review Panel (PPL
70/10546).
Whole blood, lung, and aorta COX activity assays
WT, COX-1/, and/or COX-2/ mice were euthanized with
CO2. In some cases, 30 min beforehand, animals were treated
with aspirin-lysine (Flectadol; Sanofi-Aventis, Milan, Italy) or
vehicle by tail-vein injection. Lungs were removed and snap-
frozen. Blood was collected from the inferior vena cava into
lithium heparin (17 U/ml final; Sigma-Aldrich, Gillingham,
UK), then stimulated with calcium ionophore A23187 (50
M; Sigma-Aldrich) for 30 min at 37°C. Plasma was separated
by centrifugation and the levels of the stable TXA2 break-
down product, TXB2, determined by enzyme immunoassay
(Cayman Chemical, Ann Arbor, MI, USA).
Thoracic aorta was removed and carefully cleaned of
periadventitial material. Next, 2 mm rings of aorta were
divided and allowed to equilibrate in DMEM (Sigma-Aldrich)
for 90 min, before stimulation with calcium ionophore
A23187 (50 M). After 30 min, conditioned medium was
removed for measurement of the stable prostacyclin break-
down product 6-keto-PGF1 by ELISA (Cayman Chemical).
Lungs were dissociated using a ceramic bead homogenizer
(Precellys 24; Bertin Technologies, Rockville, MD, USA) in
Tris buffer (50 mM; Sigma-Aldrich) containing phenylmeth-
anesulfonyl fluoride (1 mM; Sigma-Aldrich) and diclofenac
(1 mM; Sigma-Aldrich). Supernatants were separated by centrifu-
gation and collected for measurement of PGE2 using a
homogenous time-resolved fluorescence-based immunoassay
(Cisbio Bioassays, Codolet, France) and for 6-keto-PGF1
using ELISA as described above.
Circulating prostacyclin measurement
WT, COX-1/, and/or COX-2/ mice were treated with
lipopolysaccharide (LPS; 10 mg/kg i.p.; from Escherichia coli
055:B5; Sigma-Aldrich) or vehicle (saline). After 4 h, mice
were euthanized with CO2, and blood was collected from the
inferior vena cava. Plasma was separated by centrifugation,
and the levels of the PGI2 breakdown product, 6-keto-PGF1,
were determined by ELISA (Cayman Chemical).
COX immunohistochemistry
WT mice treated with LPS (10 mg/kg) or vehicle by intra-
peritoneal injection were euthanized with CO2 after 4 h, and
the vasculature was fixed with 5% neutral buffered formalin
(Sigma-Aldrich) by transcardiac perfusion. The thoracic aorta
was carefully removed for whole mount immunohistochemis-
try. Briefly, vessels were treated with 20% goat serum and
0.1% Triton X-100 to block nonspecific binding and perme-
abilize cells, respectively. They were then incubated, in turn,
with rabbit anti-mouse COX-2 primary antibody (1:50; 4 h;
Cayman Chemical), Alexa594-conjugated goat anti-mouse
IgG secondary antibody (1:100; 2 h; Invitrogen, Paisley, UK),
and Alexa488-conjugated rat anti-mouse CD31 antibody (1:
100; 2 h; BioLegend, London, UK) with thorough washing
with PBS between reagents. Vessels were cut open and
mounted flat using hardset aqueous medium (Vector Labs,
Peterborough, UK). The luminal surface was visualized using
a Leica SP5 inverted confocal microscope and a 40 oil-
immersion objective lens (Leica Microsystems, Wetzlar, Ger-
many). The endothelial cell layer was identified based on cell
morphology and CD31 immunoreactivity, and the back-
ground corrected fluorescence intensity of COX-2-like immu-
noreactivity was quantified using Fluorescence Lite software
(Leica). The specificity of the staining was confirmed by the
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ability of COX-2 gene deletion or specific blocking peptides
to quench immunoreactivity (5).
qRT-PCR
WT mice treated with LPS (10 mg/kg) or vehicle by intra-
peritoneal injection were euthanized with CO2 after 0, 4, 12,
18, or 24, h and the lung and aorta were immediately
removed and snap-frozen. Tissue was homogenized as above,
and RNA was extracted using a silica column-based kit
(Invitrogen). cDNA was synthesized by reverse transcription
(SuperScript II; Invitrogen) with oligo-d(T) primers. cDNA
was amplified and quantified by qPCR using TaqMan
gene expression assays (18S: Mm03928990_g1; PTGS2:
Mm00478374_m1; Invitrogen) and a Rotor Gene Q instru-
ment (Qiagen Ltd., Manchester, UK). COX-2 (Ptgs2) expres-
sion levels were normalized to 18S ribosomal RNA levels and
quantified using the comparative Ct method.
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Figure 1. COX-2 expression activity in the
vasculature and the effect of LPS. In
untreated mice, Ca2 ionophore-stimu-
lated prostacyclin release (measured as
6-keto-PGF1) by aortic segments (A) and
PGE2 formation in lung homogenates
(B) was not altered by COX-2 deletion,
but abolished by COX-1 deletion. Accord-
ingly, basal plasma levels of 6-keto-PGF1
were reduced by COX-1 but not COX-2
deletion (C). Administration of LPS (10
mg/kg) increased plasma prostacyclin
levels (C), and this effect was COX-2
dependent. LPS also produced a time-
dependent increased in aortic COX-2
(Ptgs2) gene expression (D), and this was
detectable at 4 h as an increased COX-2-
like immunoreactivity (E). LPS also pro-
duced a time-dependent increased in
lung COX-2 gene expression (F) and
neutrophil infiltration into the lung, measured as increased myeloperoxidase levels (G). Data are the means  se for
tissue from n  4–8 mice aged 10–12 wk. Data were analyzed using unpaired t test (E) or 1-way ANOVA followed by
Bonferroni’s multiple comparison test (A–C). *P 	 0.05.
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Myeloperoxidase measurement
WT mice treated with LPS (10 mg/kg) or vehicle by intraperi-
toneal injection were euthanized with CO2 after 0, 4, 12, 18 or 24
h, and the lung was immediately removed and snap-frozen.
Tissue was homogenized in PBS as above, and the myeloperox-
idase content of the supernatant determined by enzyme immu-
noassay (R&D Systems, Minneapolis, MN, USA).
Lipoxin A4 and ATL measurement by ELISA
WT, COX-1/ and COX-2/ mice (each n8) were treated
with LPS (10 mg/kg; i.p.) or vehicle. After 4 h, mice additionally
received either aspirin-lysine (10 or 100 mg/kg; i.v.) or its
vehicle. For time-course studies, WT mice (n4) were treated
with LPS (10 mg/kg; i.p.) or vehicle for 0, 4, 12, 18, or 24 h
before administration of aspirin-lysine (100 mg/kg; i.v.) or its
vehicle. After a further 30 min, mice were euthanized with CO2.
Venous blood was collected into lithium heparin, and plasma
was separated by centrifugation. Lungs and aorta were also
collected and snap-frozen before disruption with a Precellys24
homogenizer (100 mg tissue/ml) in Tris buffer (50 mM; pH
7.4) with phenylmethanesulfonyl fluoride (1 mM). Levels of
lipoxin A4 and 15-epi-lipoxin A4 in plasma and the supernatant
of lung and aorta homogenates were determined by enzyme
immunoassay (Neogen Corp., Lansing, MI, USA). To exclude
any matrix interference effects, samples were assayed for 15-epi-
lipoxin A4 both after HPLC extraction using C18 columns, as
recommended by the assay manufacturer, and after dilution 1:9
with assay buffer. For HPLC/C18 extraction, 50–100 l of
plasma was diluted in methanol-water (15%) to a final volume of
1 ml and acidified to pH 3.5. Samples were centrifuged (5°C
4000 g) and supernatant applied to a Waters HPLC SunFire
reversed phase Silica C18 column (Waters Corp., Wexford,
Ireland). Following washing with water and hexane, samples
were eluted using methyl formate, and samples were centrifuged
before supernatants were evaporated under a stream of nitro-
gen. Samples were reconstructed with ELISA buffer as in-
structed. In addition, a subset of plasma samples (n4) was
subjected to chiral analysis by liquid chromatography-tandem
mass spectrometry (chiral lipid analysis; LC-MS/MS) to deter-
mine the levels of 12(S)-HETE, 12(R)-HETE, 15(S)-HETE,
15(R)-HETE, LXA4, and 15-epi-lipoxin A4 according to the
method described below (18).
Chiral chromatography/mass spectrometry
Levels of 12(S)-HETE, 12-(R)-HETE, 15-(S)-HETE, 15-(R)-
HETE, LXA4, and 15-epi-lipoxin A4 in plasma from mice
treated with the above combinations of LPS and aspirin-lysine
were analyzed using chiral liquid chromatography coupled to
electrospray ionization tandem mass spectrometry (LC/ESI-
MS/MS) as described previously (18). Briefly, plasma samples
200–450 l) were defrosted on ice and adjusted to 15% v/v
methanol, to a final volume of 4 ml. Internal standard
12(S)-HETE-d8 (40 ng; Cayman Chemical) was added. Sam-
ples were acidified to pH 3.0 using 0.1 M HCl and then
directly loaded onto a preconditioned solid-phase extraction
cartridge (C18-E; Phenomenex, Cheshire, UK). Lipid media-
tors were eluted with methyl formate. Chiral chromatography
was performed on a LUX-1 cellulose column (3 m, 1502.0
mm; Phenomenex) using an HPLC pump (Alliance 2695;
Waters) coupled to a triple-quadrupole mass spectrometer
with electrospray probe (Quatro Ultima; Waters). Lipid me-
diators were analyzed in multiple reaction monitoring
(MRM) mode using the following transitions: 15(R)-HETE
and 15(S)-HETE m/z 319  175, 12(R)-HETE and 12(S)-
HETE m/z 319  179, LXA4 and 15-epi LXA4 m/z 351  115,
and 12(S)-HETE-d8 m/z 327  184. Results are expressed as
picograms of mediator per microliter of plasma.
Statistics and data analysis
Data were analyzed using Prism 5.01 for Mac OS X (Graph-
Pad Software, San Diego, CA, USA). Statistical significance
was determined by 1-way ANOVA with Dunnett’s post hoc test
unless otherwise stated, and data sets were considered differ-
ent if P 	 0.05.
RESULTS AND DISCUSSION
COX-1 vs. COX-2 activity in control and LPS-treated
mice
The generation of 15(R)-HETE or downstream ATL by
aspirin in vitro relies on the presence of COX-2. How-
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Figure 2. Inhibition of COX-1 and COX-2-dependent prostanoid formation by aspirin in vivo. Aspirin administration (0.1–100
mg/kg, i.v.; 30 min) produced dose-dependent inhibition of serum TXB2 formation (A) and lung homogenate PGE2 formation
(B) in tissue from WT mice, both responses that are primarily COX-1 dependent. Aspirin also produced dose-dependent
inhibition of PGE2 formation in lung homogenates from COX-1-deficient mice, in which residual prostanoid production
(
0.1% of WT levels) is mediated by COX-2 (C). In all systems, aspirin produced70% inhibition of COX activity at 100mg/kg.
Data are means  se for tissue from n  3–5 mice aged 10–12 wk.
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ever, we have recently shown in human endothelium
and in vessels of healthy mice that COX-1 rather than
COX-2 predominates (5). In the current study, we
confirm our previous observations that COX activity in
the vessel (Fig. 1A) or in the lung (Fig. 1B) is over-
whelmingly COX-1 driven (5). Similarly, as we (5) and
others (19) have shown, basal release of PGI2 in control
mice measured in plasma ex vivo is driven by COX-1
(Fig. 1C). To test our hypothesis that ATL could be a
viable biomarker of circulatory COX-2, we therefore
treated mice with LPS to increase COX-2 expression in
the endothelium above low-level basal expression. LPS
at 10 mg/kg produced a time-dependent increased in
aortic COX-2 (Ptgs2) gene expression, between 4 and
24 h (Fig. 1D), and this was detectable as an increase in
COX-2-like immunoreactivity in the aorta by 4 h (Fig.
1E). In parallel, at 4 h after LPS, plasma prostacyclin
was increased by 60 fold, which, in direct contrast to
prostacyclin under basal conditions, was predominately
COX-2 driven (Fig. 1C). Similar to the aorta, lung
COX-2 gene expression was increased by LPS between
4 and 24 h, peaking at 12 h (Fig. 1F), and this was
accompanied by an increase in leukocyte infiltration
into the lung, measured as myeloperoxidase content
(Fig. 1G).
Plasma levels of ATL and HETEs in control mice and
LPS treated mice
In rats (20) or mice (21), aspirin administration in-
creases ATL. Moreover, in healthy volunteers taking
low-dose but not medium- or high-dose aspirin for 8 wk,
increases in ATL in plasma were noted (22). These
observations provided the impetus for our study. How-
ever, to demonstrate the suitability of ATL as a useful
biomarker of COX-2 in the circulation in patients with
active cardiovascular and/or inflammatory disease, we
required a system wherein ATL could be measured
acutely after aspirin and levels detectably increased with
COX-2 induction. We first wanted to establish a phar-
TABLE 1. Aspirin does not alter plasma of aortic levels of ATL (15-epi-lipoxin A4) or LXA4 (measured by ELISA) between 0 and 24 h
after LPS treatment
Treatment LXA4 control (ng/ml) LXA4 aspirin (ng/ml) ATL control (ng/ml) ATL aspirin (ng/ml)
Plasma
Control, 0 h 1.6  0.3 1.5  0.3 6.0  0.7 4.8  0.5
LPS
4 h 6.1  0.8* 5.1  0.8* 7.4  1.1 7.3  1.3
12 h 4.3  0.7 5.7  0.8* 6.4  0.8 7.0  1.8
18 h 4.0  0.4 5.7  1.0* 5.1  0.5 7.5  1.6
24 h 2.6  0.2 4.6  0.7 3.8  0.8 4.6  0.4
Aorta homogenate
Control, 0 h 8.9  1.3 4.5  0.7 23.4  4.6 17.9  5.6
LPS
4 h 7.6  0.7 7.8  1.7 28.7  1.9 31.1  8.4
12 h 6.4  1.1 8.7  1.4 29.7  7.6 41.5  9.2
18 h 5.4  1.1 5.4  0.5 18.6  4.3 20.2  2.8
24 h 3.9  0.5 6.6  0.4 12.8  2.3 24.8  0.6
Plasma or aortic ATL levels were not altered by aspirin (100 mg/kg; 30 min) when measured by commercial ELISA between 0 and 24 h
after LPS treatment. Plasma but not aorta LXA4 levels were increased by LPS but not altered by aspirin. Data are the means  se for tissue from
n  4 mice aged 10–12 wk. Data were analyzed for the effect of time point and aspirin using 2-way ANOVA followed by Tukey’s multiple
comparison test. *P 	 0.05 vs. control.
TABLE 2. COX-1 or COX-2 deletion does not alter plasma levels of ATL (15-epi-lipoxin A4,
measured by ELISA) in control or LPS-primed mice treated with aspirin
Genotype
ATL (ng/ml)
Vehicle Aspirin LPS LPS  aspirin
Diluted plasma
WT C57Bl/6 1.2  0.1 1  0.2 1.6  0.2 1.2  0.1
COX-1/ 1.5  0.1 1.3  0.1 1.4  0.1 1.2  0.1
COX-2/ 1.5  0.3 1.3  0.2 1.6  0.1 1.4  0.1
HPLC-extracted plasma
WT C57Bl/6 1.9  0.2 1.8  0.2 2.3  0.3 1.9  0.3
COX-1/ 1.7  0.2 1.8  0.1 2.0  0.2 1.8  0.2
COX-2/ 2.1  0.2 2.1  0.2 2.1  0.4 2.0  0.3
Plasma ATL levels were not altered by aspirin (10 mg/kg), LPS, or COX-1/2 deletion when
measured by commercial ELISA in plasma diluted in buffer or extracted using HPLC and C18 columns.
Data are the means  se for tissue from n  8 mice aged 10–12 wk. Data were analyzed within each
genotype using 1-way ANOVA followed by Bonferroni’s multiple comparison test.
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macological dose of aspirin that would effectively in-
hibit COX-1 and COX-2 in mice in vivo. This was
particularly important to do since higher doses of
aspirin were found to antagonize ATL generation in
healthy human volunteers (22) and because mice are
relatively insensitive to the effects of aspirin (21, 23).
The potency of aspirin administered i.v. on COX-1
activity in vivo was measured by thromboxane forma-
tion in clotting blood (Fig. 2A) and PGE2 in lung
homogenates ex vivo (Fig. 2B). The potency of aspirin
on COX-2 activity in vivo was measured as PGE2 in lung
homogenate of COX-1/ mice (Fig. 2C). Effective
inhibition of COX-1 (Fig. 2A, B) or COX-2 (Fig. 2C) was
seen at aspirin concentrations of 10 mg/kg and greater.
In control mice, despite effectively blocking COX
activity, aspirin (10 mg/kg) did not increase plasma
Figure 3. Aspirin treatment in LPS-induced
mice does not produce detectable ATL forma-
tion in WT mouse plasma. Representative chro-
matograms for the chiral analysis of the ATL,
15-epi-lipoxin A4, lipoxin A4 (A) 12(R/S)-
HETE, (B) and 15(R/S)-HETE (C) by LC-MS/
MS. Endogenous ATL could not be detected in
plasma from WT mice treated with LPS and
aspirin (10 mg/kg) by chiral LC-MS/MS. Only
12(S)-HETE, not 12(R)-HETE or 15(R/S)-
HETE, was detectable in plasma from LPS-
treated mice. Chromatograms are representa-
tive of n  4 independent experiments.
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levels of ATL, as measured by ELISA (Tables 1 and 2).
As discussed above, control mice express very low levels
of COX-2 activity, but this could be increased by
treatment with LPS (Fig. 1). Even in mice treated with
LPS for 4 to 24 h to induce COX-2, however, aspirin (10
mg/kg) did not increase ATL in plasma (Table 1).
Similar results were obtained measuring ATL in aortic
homogenates (Table 1). Further, COX-1 or -2 deletion
did not alter plasma ATL levels (Table 2), suggesting
either that basal levels are derived from a COX-inde-
pendent pathway (15) or are an artifact of ELISA-based
measurement. Our analysis of ATL using ELISA was
further explored using chiral lipid analysis by LC-
MS/MS (Fig. 3; Table 2). Analysis of ATL and LXA4
standards showed elution peaks at 10.34 and 11.47 min,
respectively (Fig. 3A). No corresponding peaks were
seen in the plasma of LPS- and aspirin-treated WT mice
(Fig. 3 and Table 2). Our detection of ATL by ELISA
but not chiral LC-MS/MS may be explained by the
levels of sensitivity of these two assays as used: detection
limits were 0.2 ng/ml of the ELISA and 2 ng/ml for
chiral analysis (18).
In addition to COX-2 acetylation, the generation of
COX-derived ATLs requires activation of phospho-
lipase A2 to liberate the substrate arachidonic acid, and
presence of neutrophil 5-LO to metabolize 15(R)-
HETE to ATL. Clearly, in our mice treated with LPS, we
have elevated (compared to control mice) levels of
COX-2 (Fig. 1). Both 12(S)-HETE and lipoxin A4 are
metabolites of arachidonic acid, and, as such, their
formation requires activation of phospholipase A2. In
the absence of ATL being detected, increases in 12(S)-
HETE (Table 3) and lipoxin A4 (Table 1) in the plasma
of LPS-treated mice therefore provide important evi-
dence that phospholipase A2 is activated in our animals
in vivo. Our inability to detect LPS-induced changes in
plasma lipoxin A4 by chiral LC-MS/MS is likely to
reflect the lower sensitivity of this method (18).
Again, in the absence of ATL, we wanted to determine
whether the upstream aspirin triggered metabolite,
15(R)-HETE, could be used as a plasma biomarker for
increased COX-2 in the vasculature. We eluted 15(R)-
HETE and 15(S)-HETE at 43.43 and 45.01 min, respec-
tively, but neither metabolite was detected in mouse
plasma (Fig. 3C), suggesting that they were at or below the
limit of detection for the assay (2 ng/ml; Table 3).
ATL in lungs of control and LPS treated mice;
comparison with plasma levels
Aspirin-triggered 15(R)-HETE is generated by micro-
somal fractions of cells expressing COX-2 (24) and by
COX-2-expressing human endothelial cells (10) or
lung epithelial cells (25). ATL is generated when
15(R)-HETE is further metabolized by 5-LO (25). This
can be modeled in vitro by coculture of endothelial or
epithelial cells with monocytes or neutrophils (10, 20,
25, 26). While basal levels of ATL were detected by
ELISA in the plasma of mice used in our study, we were
not able to demonstrate significant increases in animals
where COX-2 had deliberately been increased using
LPS. To provide a positive control for our studies and
to better understand how this reflects generation of
ATLs in an optimized system, we measured ATL forma-
tion in the lung of LPS-treated mice. Here an optimal
setting exists where endothelial cell/epithelial cells in
which COX-2 is induced by LPS (Fig. 1D) are in contact
with primed leukocytes, whose presence was confirmed
by a 
10-fold increase in lung myeloperoxidase con-
tent (Fig. 1G). Consistent with what has been previously
shown in inflamed mouse tissue (26), we found in-
creased ATL levels in the lungs of mice treated with
aspirin (100 mg/kg) after LPS (Fig. 4) in parallel with
increased COX-2 gene expression (Fig. 1). Notably,
ATL levels were increased in a dose-dependent manner
(10010 mg/kg; Fig. 4B) and release (aspirin: 10
TABLE 3. Quantitation of plasma ATL (15-epi-lipoxin A4), LXA4, 12(R/S)-HETE, and 15(R/
S)-HETE levels by chiral chromatography mass spectrometry in plasma from aspirin (10 mg/kg)- and
LPS (10 mg/kg)-treated mice
Component Vehicle Aspirin LPS LPS  aspirin
ATL (ng/ml) ND ND ND ND
LXA4 (ng/ml) ND ND ND ND
12(S)-HETE (ng/ml)
WT C57Bl/6 13.0  2.2 12.0  2.7 36.0  7.3 38.2  10.5*
COX-1/ 11.5  1.3 10.7  1.9 37.6  5.8* 35.4  11.5
COX-2/ 12.3  3 11.1  2.8 27.8  13.7 36.8  7.5
12(R)-HETE
(ng/ml)
ND ND ND ND
15(S)-HETE (ng/ml) ND ND ND ND
15(R)-HETE
(ng/ml)
ND ND ND ND
ATL, LXA4, 12(R)-HETE, 15(S)-HETE, and 15(R)-HETE were not detectable (ND) in plasma from
any tested treatment group and genotype of mice. 12(S)-HETE was detectable in all plasma samples and
tended to be increased by LPS administration in all genotypes of mice, consistent with the ability of LPS
to increase phospholipase A2 activity in vivo. Data are the means  se for tissue from n  4 mice aged
10–12 wk. Data were analyzed within each genotype using 1-way ANOVA followed by Bonferroni’s
multiple comparison test. *P 	 0.05 vs. vehicle.
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mg/kg) was transient, with peak levels being detected
at 30 min after aspirin administration (Fig. 4A). In a
separate study using the high dose of 100 mg/kg of
aspirin, designed to directly parallel measurement of
ATL in the lungs and plasma of WT and COX-1/2-
knockout mice, we again found that aspirin increased
ATL (Fig. 5A) but not LXA4 in the lungs (Fig. 5B), or
ATL in plasma of LPS-primed WT mice (Fig. 5C). This
effect was lost in tissue from COX-2/ mice, illustrating
that ATL generation was dependent on COX-2 (Fig.
5A) rather than non-COX pathways, such as cyto-
chrome P450s, consistent with previous studies in in-
flamed mouse tissue (26). However, we also found that
the ability of aspirin to increase ATL was also lost in
tissue from COX-1/ mice. The explanation for this is
not clear but may reflect a role for COX-1 in mediating
early inflammatory events (16) that may be required to
assemble relevant cell types in proximity (e.g., endothe-
lial cells and leukocytes).
CONCLUSIONS
These studies are the first to directly address the
potential for plasma levels or ATL as a biomarker for
COX-2 in the circulation. In control mice, COX-1
drives circulating (plasma) PGI2 levels. However, when
mice are treated with LPS, COX-2 is induced and takes
a major role in circulating levels of PGI2. Basal levels of
ATL are detectable in the plasma of control and
LPS-treated mice. In our study we found that aspirin
administration in vivo could effectively inhibit COX-2
without increasing plasma levels of ATL. Clearly others
have found aspirin to increase ATL in rodents (20, 21),
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Figure 4. Aspirin produces dose- and time-dependent in-
creases in ATL (15-epi-lipoxin A4) levels in the lung of WT
mice. Administration of aspirin (10 mg/kg) to LPS-primed
WT mice produced an increase in ATL levels in lung homog-
enates (A), which peaked at 30 min then declined slowly. In
independent experiments, in LPS-primed mice, lung ATL
levels 30 min after aspirin administration were found to
increase in a dose-dependent manner (B). Data are the
means  se for tissue from n  4–8 mice aged 10–12 wk.
Data were analyzed using 1-way ANOVA followed by Bonfer-
roni’s multiple comparison test. *P 	 0.05.
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Figure 5. ATL (15-epi-lipoxin A4) formation in lung homog-
enates is COX-2 dependent. In lung homogenates from WT
mice, administration of aspirin (100 mg/kg) and LPS (10
mg/kg) but neither on its own, produced an increase in
ATL levels (A) but not LXA4 levels (B). This effect was
abolished by deletion of COX-2 or COX-1. In the same
animals, ATL levels in plasma were not altered by any
treatment or COX-1/2 deletion (C). Data are the means 
se for tissue from n  6 mice aged 10–12 wk. Data were
analyzed using 1-way ANOVA followed by Bonferroni’s
multiple comparison test. *P 	 0.05.
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which may well have utilized models where COX-2 and
5-LO were optimized. However, our study suggests that
in a controlled model where low COX-2 (control mice)
and increased COX-2 (LPS-treated mice) are directly
compared, plasma levels of ATL do not correlate with
COX-2 step changes. Aspirin treatment did significantly
increase COX-2 mediated ATL in the lungs of the same
mice and this correlated with COX-2 induction; how-
ever, the usefulness of lung ATL as a biomarker of
COX-2 expression is questionable given that more
direct measures are possible where tissue is available.
Taken together, these data do not support the concept
that plasma ATL can be used as a biomarker for the
noninvasive assessment of vascular COX-2 expression in
patients.
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